Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This early-stage trial tests a new drug called TQB3142 in 66 adults with advanced tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look f…

This study tests whether a new drug called TQ-B3234 can shrink non-surgical nerve tumors (plexiform neurofibromas) in adults with neurofibromatosis type 1 (NF1). About 177 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces tumor si…

This clinical trial is testing a new drug called TQB6411 in people with advanced lung cancer. The study has two phases: first to find the best dose, then to see how well it works. About 465 participants will receive the drug every 21 days. Researchers will measure tumor shrinkage…

This phase II trial is testing whether a combination of two drugs—benmelstobart (an immunotherapy) and anlotinib (a targeted therapy)—can shrink tumors in people with advanced or inoperable alveolar soft part sarcoma, a rare cancer. The study will enroll 33 participants aged 14 a…

This early-phase study tests a new oral drug, TQB3205, in 156 adults with advanced malignant tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking for any signs that the drug shrinks tumors. Pa…

This early-stage study is testing a drug called TQ05105 in people with mild or moderate liver impairment and healthy volunteers. The goal is to see how the liver affects the drug's levels in the body and check for safety. 24 participants will receive a single dose and be monitore…

This phase 2 trial tests an injection called TQH2929, a lab-made antibody that blocks inflammation, in 36 adults having a sudden, severe flare of generalized pustular psoriasis (GPP). Half get the drug, half get a placebo. The main goal is to see if the drug clears pustules withi…

This study tests a new drug called LM-108, given with an immunotherapy (penpulimab) and two chemotherapy drugs, in people with advanced pancreatic cancer. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 72 adults with advanced pancre…

This study tests a new drug called TQB6411 in people with advanced esophageal cancer that has worsened after standard treatments. The drug is designed to target and attack cancer cells. The trial has two parts: first to find a safe dose, then to see if it shrinks tumors. About 10…

This study tests a drug called TQH2722, a lab-made antibody that blocks inflammation, for people with severe chronic sinusitis (with or without nasal polyps). About 120 adults who completed a prior TQH2722 study will receive either 300mg or 600mg injections over a long period. Re…

This early-stage study tests an experimental oral drug called TQB3019 in 80 adults with advanced malignant tumors that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors…

This study tests a new drug called TQB2825, a bispecific antibody that helps immune cells attack lymphoma cells, combined with standard R-CHOP chemotherapy. The trial enrolls 90 adults with untreated or relapsed/refractory diffuse large B-cell lymphoma. Researchers will measure h…

This early-phase study tests a new oral drug, TQB3122, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow disease. About 86 adults aged 18-75 wi…

This study tests whether the experimental drug AL2846 can slow cancer growth in people with advanced thyroid cancer that no longer responds to radioiodine or previous targeted therapy. About 144 participants will receive either AL2846 or a placebo. The main goal is to see how lon…

This study tests whether combining two experimental drugs (TQ05105 and TQB3617) can safely shrink the spleen and improve symptoms in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. About 92 adults will take the pills daily, and researchers will…

This study tests a new drug, rovadicitinib, for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have tried at least two prior treatments. The goal is to see if rovadicitinib improves symptoms better than sta…

This early-stage study tests a new drug, TQB3002, in 150 adults with advanced cancers that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body and look …

This early-phase trial tests a new drug called TQF3250 in 66 healthy adults with high blood sugar. The drug is designed to activate only certain parts of the GLP-1 receptor, aiming for better blood sugar control with fewer side effects. The main goal is to check safety and how th…